Conditions: Mature B-Cell Neoplasm; Non Hodgkin Lymphoma; DLBCL; Waldenstrom Macroglobulinemia; MALT Lymphoma; Follicular Lymphoma; Pediatric-Type Follicular Lymphoma; IRF4 Gene Rearrangement; EBV-Positive DLBCL, Nos; Burkitt Lymphoma; Plasmablastic Lymphoma; High-grade B-cell Lymphoma; Primary Cutaneous Follicle Center Lymphoma; Primary Effusion Lymphoma; Mantle Cell Lymphoma; DLBCL Germinal Center B-Cell Type; Primary Mediastinal Large B Cell Lymphoma; T-Cell/Histiocyte Rich Lymphoma; ALK-Positive Large B-Cell Lymphoma; Primary Cutaneous Diffuse Large B-Cell Lymphoma; Splenic Marginal Zone Lymphoma; Chronic Lymphocytic Leukemia; Nodal Marginal Zone Lymphoma; HHV8-Positive DLBCL, Nos; Lymphoplasmacytic Lymphoma; Duodenal-Type Follicular Lymphoma
Interventions: Drug: SGR-1505
Sponsors: Schrödinger, Inc.
**RECRUITING NOW**
Interventions: Drug: SGR-1505
Sponsors: Schrödinger, Inc.
**RECRUITING NOW**
Source: View full study details on ClinicalTrials.gov
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
